Takeda Launches First Asian Innovation Capability Center in Bengaluru, Focusing on AI and Digital Health Solutions

Takeda's Strategic Expansion into India

Takeda, a global biopharmaceutical leader, has officially launched its first Innovation Capability Center (ICC) in Asia, located in Bengaluru, India. This strategic move marks a significant step in Takeda's global digital transformation journey, aiming to harness the power of artificial intelligence (AI) and other digital technologies to accelerate research and development and improve healthcare outcomes 1

1

2

The Innovation Capability Center: A Hub for Digital Health Solutions

The Bengaluru ICC is designed to be a powerhouse of innovation, focusing on developing cutting-edge digital solutions that will support Takeda's global operations. Key areas of focus include:

1. Artificial Intelligence and Generative AI: Enhancing efficiency and predictive analytics in healthcare
2. Device Engineering and Application Virtualization: Driving innovation in product development and patient-centric solutions
3. Data Science and Visualization: Enabling data-driven decision-making for improved patient outcomes 2

   2

Gabriele Ricci, Chief Data and Technology Officer at Takeda, emphasized the importance of this new center, stating, "The launch of our Bengaluru ICC is a pivotal moment for Takeda's digital transformation journey" 1

1

Talent Acquisition and Job Creation

The Bengaluru ICC aims to employ 750 professionals by the end of the year, including software engineers, data scientists, and cybersecurity experts. This move not only strengthens Takeda's global innovation capabilities but also contributes to job creation in India's thriving tech sector 1

1

3

Strategic Choice of Location

Takeda chose Bengaluru for its first Asian ICC due to the city's robust talent pool in data, digital, and technology, as well as its unique ecosystem of academia, startups, and tech partners. Tilak Banerjee, Head of Takeda ICC India, stated, "India was a natural choice for Takeda's first ICC in Asia" 2

2

3

Global Network of Innovation Centers

The Bengaluru ICC is Takeda's third such center globally, complementing existing hubs in Mexico and Slovakia. Sanjay Patel, Global Head of Innovation Capability Solutions and Services, described the Bengaluru site as "our flagship ICC, forming part of a network that is the digital heart of Takeda" 1

1

Related Stories

Takeda inks $1.7 billion Iambic deal to accelerate AI drug discovery for cancer treatments

Pfizer Launches Global Commercial Analytics Centre in India

Reltio Expands Global Footprint with New AI-Focused R&D Hub in Bengaluru

Amgen to Establish Cutting-Edge Technology and Innovation Center in Hyderabad

Impact on Healthcare and Patient Care

The solutions developed at the ICC are expected to have a wide-ranging impact on various aspects of healthcare:

1. Accelerating drug discovery and development processes
2. Improving clinical trial efficiency
3. Enhancing manufacturing processes
4. Developing innovative devices and solutions tailored to patients' needs
5. Creating a global platform for healthcare professional (HCP) data
6. Developing scalable, multi-language tools to enhance patient support and care experiences 1

   1

   3

   3

Future Plans and Expansion

Takeda's commitment to innovation extends beyond the ICC launch. The company plans to expand its focus on therapeutic areas such as inflammation, oncology, and rare conditions. Additionally, Takeda is preparing to launch its Dengue vaccine, Qdenga, in Indian markets by 2026, leveraging local manufacturing under the 'Make in India' initiative 3

3

This strategic expansion in India aligns with Takeda's global mission to deliver life-transforming treatments to patients and its ambition to become one of the most trusted, values-based, R&D-driven biopharmaceutical companies in the world 2

2